Saturday 17 October 2026
Export XGN’s income statement to Excel — free account
Exagen Inc.
XGN Healthcare Diagnostics & Research
Exagen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.6 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 15.9%, EPS grew 38.1%, free cash flow grew 211.3% and total debt rose 6.44%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
7.65
0.91
−10.63%
Follow XGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.58 | 1.05 | 1.97 | 3.96 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
28.18 | (6.87) | (43.50) | 85.64 | |
P/B ratio |
9.20 | 4.96 | 7.51 | 13.90 | |
Price to Tangible BV |
16.75 | 8.02 | 10.98 | 19.96 | |
EV/Sales |
1.58 | 1.09 | 1.86 | 3.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(17.27) | (5.59) | (9.08) | (23.57) | |
EV/FCF |
(14.81) | (5.29) | (8.68) | (21.99) | |
Quick Ratio |
2.75 | 2.97 | 3.04 | 3.63 | |
Current Ratio |
3.18 | 3.47 | 3.45 | 4.08 | |
Net Debt/EBITDA |
0.17 | (1.56) | 1.85 | 5.07 | |
Debt/Assets |
47.09% | 47.47% | 42.86% | 39.92% | |
Debt/Equity |
2.00 | 1.71 | 1.43 | 1.38 | |
Asset Turnover |
1.29 | 1.48 | 1.30 | 1.20 | |
Operating CF/Net income |
(1.25) | 2.63 | 0.64 | (0.42) | |
Capex/Depreciation |
(0.57) | (0.16) | (0.03) | (0.27) | |
Interest Coverage |
(1.43) | (2.69) | (3.74) | (2.35) | |
Research and Development Expense of Revenue |
7.15% | 8.97% | 0.00% | 10.03% | |
Selling, General and Administrative Expense of Revenue |
62.75% | 69.72% | 74.70% | 66.37% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
4.91% | 3.78% | 4.24% | 3.44% | |
Graham Net Nets |
0.03 | 0.08 | 0.06 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(17.42%) | (29.67%) | (15.13%) | (8.37%) | |
Free Cash Flow Yield |
(6.74%) | (19.73%) | (10.87%) | (4.36%) | |
Revenue per Share |
0.83 | 0.73 | 0.77 | 0.75 | |
Operating CF per Share |
0.17 | (0.44) | (0.14) | 0.13 | |
Capex per Share |
(0.02) | (0.01) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.14 | (0.45) | (0.14) | 0.12 | |
Cash per Share |
1.02 | 0.90 | 1.49 | 1.55 | |
Shareholders Equity per Share |
0.51 | 0.61 | 0.81 | 0.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.51 | 0.61 | 0.81 | 0.79 | |
Free Cash Flow |
3.45 | (10.64) | (3.05) | 2.67 | |
Working Capital |
29.40 | 31.02 | 34.73 | 39.70 | |
Capital Expenditures |
(0.54) | (0.23) | (0.03) | (0.27) | |
Net Current Asset Value |
3.14 | 6.06 | 8.32 | 7.90 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.34 | 15.25 | 9.35 | 10.24 | |
Average Payables |
3.47 | 4.33 | 4.15 | 2.33 | |
Average Assets |
55.35 | 46.13 | 51.36 | 53.21 | |
Average Common Equity |
16.63 | 10.42 | 13.49 | 15.50 |
Columns are period end dates